Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probing 3-Amino-2H-Azaindazoles as Allosteric Inhibitors of the Protein Tyrosine Phosphatase SHP2.

ChemMedChem·2026
Same author

Non-Temperature-Induced Antitumor Effects of Amplitude-Modulated Radiofrequency: Molecular and Functional Synergies with Radiotherapy.

Cancers·2026
Same author

Mapping the SHP2 Allosteric Pocket With Target-Biased Covalent Fragments.

Chembiochem : a European journal of chemical biology·2026
Same author

Integrated left ventricular multi-omics landscape of human cardiometabolic HFpEF.

Cardiovascular research·2026
Same author

The Regulatory Interplay of the Colorectal Cancer Biomarkers MACC1 and IER2 and Its Impact on Metastatic Cancer Survival.

Biomolecules·2026
Same author

Unlocking the Multifaceted Role of CB<sub>1</sub>R in the Endocannabinoid System with Labeled Chemical Probes.

Chimia·2026

Related Experiment Video

Updated: Sep 12, 2025

Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model
07:03

Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model

Published on: February 3, 2021

2.8K

Novel High-Throughput Screen Identified S100A4 Inhibitors for Anti-Metastatic Therapy.

Paul Curtis Schöpe1, Nina Heisterkamp1, Devin Schütz1

  • 1Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, and Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Str. 10, 13125 Berlin, Germany.

International Journal of Biological Sciences
|August 6, 2025
PubMed
Summary

Researchers identified a new compound, E12, that effectively inhibits S100A4 expression and reduces colorectal cancer metastasis in cell and animal models. This discovery offers a promising therapeutic strategy for advanced colorectal cancer patients.

Keywords:
HTSS100A4colorectal cancermetastasistargeted therapy

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

2.2K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K

Related Experiment Videos

Last Updated: Sep 12, 2025

Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model
07:03

Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model

Published on: February 3, 2021

2.8K
High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

2.2K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Colorectal cancer (CRC) metastasis is a major cause of cancer mortality.
  • S100A4 protein is a key driver of CRC metastasis.
  • Targeting S100A4 offers a potential therapeutic strategy for CRC.

Purpose of the Study:

  • To identify novel compounds that inhibit S100A4 transcription.
  • To evaluate the efficacy of identified compounds in reducing CRC metastasis.
  • To assess the therapeutic potential of the lead compound E12 in preclinical models.

Main Methods:

  • High-throughput screening (HTS) of 105,600 compounds using an S100A4 promoter-luciferase assay in HCT116 cells.
  • In vitro assessment of S100A4 inhibition, wound healing, migration, proliferation, and viability.
  • In vivo evaluation of compound E12 in a HCT116 xenograft mouse model.

Main Results:

  • HTS identified novel S100A4 transcriptional inhibitors.
  • Lead compound E12 demonstrated potent S100A4 inhibition at mRNA and protein levels (EC50 < 1 µM).
  • E12 restricted metastatic abilities in vitro and reduced metastasis in vivo, with tolerable toxicity.

Conclusions:

  • Compound E12 shows significant potential for S100A4-targeted therapy against colorectal cancer metastasis.
  • E12 represents a promising candidate for improving outcomes in patients with metastatic CRC.
  • Further development of E12 could lead to a novel treatment for advanced colorectal cancer.